Deal funds development of dendritic cell-based brain cancer vaccine
By Devika Patel
Knoxville, Tenn., Feb. 23 - ImmunoCellular Therapeutics, Ltd. said it arranged a private placement of units. The deal will raise about $8.1 million.
The company will sell about 5.2 million units of one common share and a half-share warrant at $1.55 apiece. The whole warrants are exercisable at $2.25 for five years. The strike price reflects an 11.94% premium to the Feb. 22 closing share price of $2.01.
Summer Street Research Partners and Dawson James Securities, Inc. are the agents.
Proceeds will be used to accelerate the development of ICT-107, the company's dendritic cell-based brain cancer vaccine, as well as for general corporate purposes.
ImmunoCellular, based in Los Angeles, develops cellular treatments for brain cancer and neurodegenerative disorders.
| Issuer: | ImmunoCellular Therapeutics, Ltd.
|
| Issue: | Units of one common share and a half-share warrant
|
| Amount: | $8.1 million (approximate)
|
| Units: | 5.2 million (approximate)
|
| Price: | $1.55
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $2.25
|
| Agents: | Summer Street Research Partners and Dawson James Securities, Inc.
|
| Pricing date: | Feb. 23
|
| Stock symbol: | OTCBB: IMUC
|
| Stock price: | $2.01 at close Feb. 22
|
| Market capitalization: | $37.6 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
